Nasdaq Surf News Today

Surface Oncology (NASDAQ:SURF – Get Free Report) and Eastgate Biotech (OTCMKTS:ETBI – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Profitability This table compares Surface Oncology and Eastgate […]

Surface Oncology (NASDAQ:SURF – Get Free Report) and Eastgate Biotech (OTCMKTS:ETBI – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Analyst Recommendations This is a breakdown of current […]

Surface Oncology, Inc. (NASDAQ:SURF – Get Free Report) was the target of a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 448,400 shares, a decrease of 44.6% from the June 15th total of 809,000 shares. Based on an average daily volume of 673,300 shares, […]

Surface Oncology, Inc. (NASDAQ:SURF – Get Rating) – Research analysts at HC Wainwright lifted their FY2027 EPS estimates for shares of Surface Oncology in a report released on Friday, May 5th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.21 per share for the year, up from their prior […]

Susquehanna International Group LLP boosted its stake in shares of Surface Oncology, Inc. (NASDAQ:SURF – Get Rating) by 108.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 49,815 shares of the company’s stock after buying an additional 25,903 shares during the period. Susquehanna International Group […]

Eagle Rock Investment Company LLC raised its position in shares of Surface Oncology, Inc. (NASDAQ:SURF – Get Rating) by 90.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,000 shares of the company’s stock after buying an additional 20,000 shares during the quarter. […]

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...

Surface Oncology (NASDAQ:SURF – Get Rating)‘s stock had its “buy” rating reissued by Jonestrading in a research note issued on Sunday, TipRanks reports. They presently have a $12.00 target price on the stock. Several other research analysts have also issued reports on the company. TheStreet lowered Surface Oncology from a “c-” rating to a “d” […]

Surface Oncology, Inc. (NASDAQ:SURF – Get Rating) was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 2,650,000 shares, an increase of 27.4% from the April 15th total of 2,080,000 shares. Approximately 7.1% of the shares of the company are short […]

CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing...